Deciphera Pharmaceuticals (NASDAQ:DCPH) was downgraded by stock analysts at BidaskClub from a “hold” rating to a “sell” rating in a research report issued on Tuesday.

Other equities analysts also recently issued research reports about the stock. Canaccord Genuity set a $55.00 price objective on shares of Deciphera Pharmaceuticals and gave the stock a “buy” rating in a research report on Monday, August 13th. Zacks Investment Research raised shares of Deciphera Pharmaceuticals from a “hold” rating to a “buy” rating and set a $41.00 price target on the stock in a research note on Tuesday, July 24th. SunTrust Banks assumed coverage on shares of Deciphera Pharmaceuticals in a research note on Thursday, July 5th. They set a “buy” rating on the stock. Cantor Fitzgerald assumed coverage on shares of Deciphera Pharmaceuticals in a research note on Thursday, September 6th. They set a “buy” rating and a $53.00 price target on the stock. Finally, Guggenheim assumed coverage on shares of Deciphera Pharmaceuticals in a research note on Monday. They set a “buy” rating on the stock. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and ten have assigned a buy rating to the company. The company presently has an average rating of “Buy” and an average target price of $50.10.

Shares of Deciphera Pharmaceuticals stock opened at $34.74 on Tuesday. The firm has a market cap of $1.38 billion and a price-to-earnings ratio of -11.62. The company has a quick ratio of 18.44, a current ratio of 18.44 and a debt-to-equity ratio of 0.05. Deciphera Pharmaceuticals has a one year low of $15.15 and a one year high of $45.61.

Deciphera Pharmaceuticals (NASDAQ:DCPH) last announced its quarterly earnings data on Tuesday, August 7th. The company reported ($0.65) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.68) by $0.03. equities research analysts forecast that Deciphera Pharmaceuticals will post -2.59 earnings per share for the current year.

Several large investors have recently bought and sold shares of the company. Bank of New York Mellon Corp grew its stake in shares of Deciphera Pharmaceuticals by 139.5% during the 2nd quarter. Bank of New York Mellon Corp now owns 56,442 shares of the company’s stock worth $2,221,000 after purchasing an additional 32,878 shares during the period. Jane Street Group LLC acquired a new position in shares of Deciphera Pharmaceuticals during the 2nd quarter worth $1,112,000. Nexthera Capital LP acquired a new position in shares of Deciphera Pharmaceuticals during the 2nd quarter worth $5,108,000. Orbimed Advisors LLC grew its stake in shares of Deciphera Pharmaceuticals by 30.8% during the 2nd quarter. Orbimed Advisors LLC now owns 2,005,700 shares of the company’s stock worth $78,924,000 after purchasing an additional 472,800 shares during the period. Finally, PointState Capital LP acquired a new stake in Deciphera Pharmaceuticals in the 2nd quarter valued at about $6,863,000. 53.49% of the stock is currently owned by institutional investors and hedge funds.

About Deciphera Pharmaceuticals

Deciphera Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response of various cancer therapies. The company's lead drug candidate is DCC-2618, which is in Phase III trial for the treatment of gastrointestinal stromal tumors; and that is in Phase I trial for treating advanced systemic mastocytosis, gliomas, and other solid tumors.

See Also: Outstanding Shares and The Effect on Share Price

Analyst Recommendations for Deciphera Pharmaceuticals (NASDAQ:DCPH)

Receive News & Ratings for Deciphera Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Deciphera Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.